22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
In a departure from decisions in recent years, the California high court has finally imposed some li...
Read More >
The U.S. Court of Appeals for the 3rd Circuit recently vacated a district court’s order compelling ...
Read More >
In a recent judgement by the Supreme Court, the circumstances under which a court may intervene and ...
Read More >
Thanks to a constitutional provision that requires Florida to adjust its minimum wage each year to m...
Read More >
The answer is not as much as you may think. Much of the recent media coverage of California’s Assem...
Read More >
Construction projects in Philadelphia now need to grapple with the City’s March 22 updated “Busine...
Read More >